

Published in final edited form as:

*J Pathol.* 2012 September ; 228(1): 77–87. doi:10.1002/path.4054.

## Sildenafil reduces respiratory muscle weakness and fibrosis in the *mdx* mouse model of Duchenne muscular dystrophy

Justin M Percival<sup>1,\*</sup>, Nicholas P Whitehead<sup>1</sup>, Marvin E Adams<sup>1</sup>, Candace M Adamo<sup>2</sup>, Joseph A Beavo<sup>2</sup>, and Stanley C Froehner<sup>1</sup>

<sup>1</sup>Department of Physiology and Biophysics, University of Washington, Seattle, WA 98195, USA

<sup>2</sup>Department of Pharmacology, University of Washington, Seattle, WA 98195, USA

### Abstract

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy caused by mutations in the dystrophin gene. Loss of dystrophin initiates a progressive decline in skeletal muscle integrity and contractile capacity which weakens respiratory muscles including the diaphragm, culminating in respiratory failure, the leading cause of morbidity and mortality in DMD patients. At present, corticosteroid treatment is the primary pharmacological intervention in DMD, but has limited efficacy and adverse side effects. Thus, there is an urgent need for new safe, cost-effective, and rapidly implementable treatments that slow disease progression. One promising new approach is the amplification of nitric oxide–cyclic guanosine monophosphate (NO–cGMP) signalling pathways with phosphodiesterase 5 (PDE5) inhibitors. PDE5 inhibitors serve to amplify NO signalling that is attenuated in many neuromuscular diseases including DMD. We report here that a 14-week treatment of the *mdx* mouse model of DMD with the PDE5 inhibitor sildenafil (Viagra<sup>®</sup>, Revatio<sup>®</sup>) significantly reduced *mdx* diaphragm muscle weakness without impacting fatigue resistance. In addition to enhancing respiratory muscle contractility, sildenafil also promoted normal extracellular matrix organization. PDE5 inhibition slowed the establishment of *mdx* diaphragm fibrosis and reduced matrix metalloproteinase-13 (MMP-13) expression. Sildenafil also normalized the expression of the pro-fibrotic (and pro-inflammatory) cytokine tumour necrosis factor  $\alpha$  (TNF $\alpha$ ). Sildenafil-treated *mdx* diaphragms accumulated significantly less Evans Blue tracer dye than untreated controls, which is also indicative of improved diaphragm muscle health. We conclude that sildenafil-mediated PDE5 inhibition significantly reduces diaphragm respiratory muscle dysfunction and pathology in the *mdx* mouse model of Duchenne

Copyright © 2012 Pathological Society of Great Britain and Ireland.

\*Correspondence to: Justin M Percival, Department of Physiology and Biophysics, University of Washington, Box 357290, Seattle, WA 98195-7290, USA. justin.m.percival@gmail.com.

No conflicts of interest were declared.

#### Author contribution statement

All authors made substantial contributions to experimental design and analysis and interpretation of data. JMP, NPW, MEA, and CA acquired data. All listed coauthors were involved in drafting the manuscript and approving the final version to be published.

#### SUPPORTING INFORMATION ON THE INTERNET

The following supporting information may be found in the online version of this article.

Supplementary methods

Figure S1. Chronic sildenafil has no significant impact on *mdx* tibialis anterior muscle strength.

Figure S2. Chronic sildenafil treatment did not impact the numbers of central nucleated muscle cells in the *mdx* tibialis anterior hindlimb muscle.

muscular dystrophy. This study provides new insights into the therapeutic utility of targeting defects in NO–cGMP signalling with PDE5 inhibitors in dystrophin-deficient muscle.

## Keywords

dystrophin; *mdx*; nitric oxide; cGMP; sildenafil; PDE5; fibrosis; TNF $\alpha$ ; MMP-13; diaphragm

## Introduction

Duchenne muscular dystrophy (DMD) is a common neuromuscular disease caused by mutations in the dystrophin gene [1]. DMD patients exhibit progressive skeletal muscle degeneration and weakness as well as cardiomyopathy [2]. Dystrophin-deficient muscle exhibits chronic inflammation and over time, muscle cells are steadily replaced with fibrotic and fatty tissue [3–5]. Progressive endomysial fibrosis, the excessive deposition of extracellular matrix proteins collagen I and fibronectin around muscle cells, impairs normal muscle contractility, vascularization, and regeneration [2,5–7]. Fibrosis exacerbates both skeletal and cardiac muscle dysfunction and presents an important target for therapeutic intervention. Progressive respiratory muscle (diaphragm and intercostal) weakness leads to respiratory failure, the leading cause of morbidity and mortality in DMD patients. Cardiac failure, resulting from either cardiomyopathy or arrhythmias, is the second major cause of mortality in DMD [2].

Currently, corticosteroids constitute the primary treatment option for muscle dysfunction in DMD, but they exhibit limited efficacy, with serious side effects. The need for new treatments has led to a focus on pharmacological enhancement of nitric oxide–cyclic guanosine monophosphate (NO–cGMP) signalling pathways in dystrophic animals. NO is indispensable for muscle integrity and function. In skeletal muscle, NO is synthesized by neuronal nitric oxide synthase mu and beta (nNOS $\mu$  and nNOS $\beta$ ), and regulates vascular function, muscle mass, fatigue resistance, atrophy, and fibre type [8–14]. Loss of dystrophin in both DMD patients and the *mdx* mouse model of DMD reduces nNOS $\mu$  expression and prevents its normal localization, thereby inhibiting the vasoregulatory role of nNOS $\mu$  and causing vascular dysfunction [8,13,15–18]. In active muscle, disruption of contraction-coupled nNOS $\mu$  signalling to the vasculature impairs muscle perfusion, causing ischaemic muscle damage and exaggerated inactivity after mild exercise [8,19,20]. Genetic enhancement of nNOS expression attenuates skeletal muscle inflammation and necrosis, improves exercise performance, and reduces cardiac fibrosis and contractile dysfunction in *mdx* mice [21–23]. These studies provide a strong rationale for determining the therapeutic utility of agents that amplify NO signalling in dystrophin-deficient muscle.

A major function of nNOS-derived NO is to stimulate cGMP production. This can be mimicked with phosphodiesterase 5 (PDE5) inhibitors such as sildenafil (Viagra<sup>®</sup>/Revatio<sup>®</sup>) and tadalafil (Cialis<sup>®</sup>). These FDA-approved vasodilators are used to treat erectile dysfunction (considered an early clinical sign and risk factor of cardiovascular disease), pulmonary hypertension, and heart failure [24]. Low (pico-nanomolar) concentrations of NO bind and activate the ‘NO receptor’ soluble guanylyl cyclase (sGC), which amplifies the NO

signal by synthesizing  $\mu\text{M}$  levels of cGMP. Downstream targets of cGMP include protein kinase G, cyclic nucleotide-gated ion channels, and cGMP-activated PDEs [25,26]. PDE5 degrades cytosolic cGMP, thereby attenuating NO signalling intensity. Thus, inhibiting PDE5 can raise cytosolic cGMP levels and indirectly amplify NO signalling.

We and others have used PDE5 inhibitors to amplify NO signalling in *mdx* mice, leading to a clinical trial to test the impact of PDE5 inhibition on DMD-associated cardiomyopathy [27] (ClinicalTrials.gov identifier: NCT01168908). Sildenafil enhanced sarcolemmal integrity and rapidly reversed left ventricle dysfunction in *mdx* hearts [27,28]. Tadalafil decreased contraction-induced ischaemic damage in *mdx* muscle [19]. Acute administration of sildenafil enhanced *mdx* mouse activity after moderate exercise by a nNOS $\mu$ -dependent mechanism [20]. While acute application of sildenafil shows promise as a therapeutic approach to dystrophy, the impact of chronic administration of sildenafil on skeletal muscle remains unknown. In the present study, we show that chronic sildenafil treatment improves respiratory muscle pathology and function.

## Materials and methods

### Animal models

All experimental procedures performed on mice were approved by the Institutional Animal Care and Use Committee of the University of Washington. Dystrophin-deficient C57BL/10ScSn-Dmd<sup>*mdx*</sup>/J (*mdx*) mice and C57BL/10ScSn/J strain controls were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All comparisons were made between age-matched male mice.

### Sildenafil administration

The PDE5 inhibitor sildenafil citrate (Pfizer Inc., New York, NY, USA) was administered in the drinking water *ad libitum* (400 mg/l) to wild-type and *mdx* mice (up to 5 per cage) for 14 weeks from 3 weeks of age. Using this approach, the average concentration of circulating sildenafil was  $70 \pm 0.05$  nM over a 24-h period [27].

### Diaphragm muscle contractile function

Diaphragm strength (specific force) and fatigue resistance were determined from 2–3 mm wide diaphragm strips. Strips were continually perfused with buffer (121 mM NaCl, 5 mM KCl, 1.8 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 0.4 mM NaH<sub>2</sub>PO<sub>4</sub>, 24 mM NaHCO<sub>3</sub>, and 5.5 mM glucose) and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub> (pH 7.4) at room temperature. A length–force curve was then determined by tetanic contractions (120 Hz, 300 ms duration), spaced 1 min apart to determine  $L_0$ , the length at which maximum tetanic force is generated. Muscle fibre length ( $L_f$ ) at  $L_0$  is measured for calculation of specific force (maximal tetanic force output normalized to muscle cross-sectional area). Diaphragm strips were then subjected to a fatigue protocol involving repetitive stimulation at 1 Hz for 45 s. Force recovery was measured at 1-min intervals up to 10 min.

### Evans Blue dye exclusion and serum creatine kinase activity assays

Evans Blue dye (EBD), a membrane-impermeant tracer dye, is a commonly used marker of skeletal muscle membrane permeability and integrity. A 10 mg/ml stock solution of EBD was prepared in PBS. A single dose (0.25 µg EBD per g of body weight) was administered by intraperitoneal injection. Mice were sacrificed 18 h later and whole diaphragms were dissected, mounted, and imaged. EBD levels were quantified using IMAGE J software V1.44P. Serum creatine kinase activity was determined as described previously [12].

### Western immunoblotting, immunohistochemistry, histology and the degeneration/regeneration index assay, and quantitative real-time polymerase chain reaction assays

These methods are described in the Supplementary methods.

### Statistics

Numbers of male mice analysed are provided in the figure legends. Data are presented as mean ± standard error of the mean. Unpaired *t*-tests with Welch's correction for unequal variance were used for pairwise comparisons of specific force output. Unpaired *t*-tests were also used for analyses of fold changes in qPCR arrays according to the manufacturer's instructions. A repeat measures ANOVA was used to analyse force deficits during fatigue experiments, using time and treatment as variables. In all other experiments, one-way ANOVA followed by Tukey's multiple comparison *post-hoc* tests were used to determine significant differences between groups. The significance level was set at  $p < 0.05$ .

## Results

### Sildenafil increases *mdx* diaphragm strength, but has no impact on fatigue resistance

Respiratory failure, originating primarily from diaphragm weakness, is the major cause of mortality in DMD. We tested whether 14 weeks of sildenafil treatment could increase *mdx* diaphragm muscle strength. The *mdx* diaphragm is particularly informative because it exhibits the most severe dystrophic phenotype including excessive weakness, fatigability, and fibrosis observed in DMD patients [29,30]. Sildenafil did not affect wild-type diaphragm specific force, a measure of intrinsic muscle strength (Figure 1A). As expected, *mdx* diaphragms generated only ~50% ( $p < 0.0001$ ) of the force of wild-type diaphragms (Figure 1A). However, sildenafil-treated *mdx* diaphragms exhibited a significant increase in specific force and were ~15% stronger ( $p < 0.01$ ) than control *mdx* diaphragms (Figure 1A). By comparison, sildenafil is more effective than conventional steroid therapy, which does not improve *mdx* diaphragm specific force [31,32]. Thus, a 15 % improvement is very important in the context of *mdx* muscle function and compares very favourably with existing steroid therapy. Also, it is useful to compare the average specific force deficit between age-matched wild-type and *mdx* hindlimb muscles, which ranges from 20% to 25% (Supplementary Figure 1A) [33,34]. Steroids increase *mdx* hindlimb muscle specific force by about 26 %, whereas sildenafil did not significantly impact *mdx* tibialis anterior hindlimb strength (Supplementary Figure 1A) [35]. Thus, the impact of sildenafil on strength appears muscle-specific. These data suggest that sildenafil provides a significant enhancement of dystrophin-deficient diaphragm muscle strength.

To further understand the impact of sildenafil on diaphragm contractility, we investigated its impact on diaphragm fatigue. Given that nNOS pathways promote muscle fatigue resistance and exercise capacity in both normal and *mdx* mice, we hypothesized that sildenafil would increase fatigue resistance in *mdx* mice [11,12,20,23,36]. Sildenafil had no impact on wild-type diaphragm fatigue (Figure 1B). As expected, *mdx* diaphragms were significantly less fatigue-resistant than controls (Figure 1B). Exaggerated *mdx* diaphragm fatigue was characterized by significant force deficits during both repetitive stimulation ( $p < 0.05$ ) and recovery phases ( $p < 0.0001$ ) compared with wild-type controls (Figures 1B and 1C). During the fatigue protocol, sildenafil had no impact on the decline of normalized force generation during the repetitive stimulation phase or on the marked post-exercise weakness of the recovery phase in either wild-type or *mdx* muscle (Figure 1B). On average, *mdx* muscle final force output levelled out at 37% of the initial force compared with 65% for wild type controls, demonstrating excessive muscle fatigue (Figure 1C). Final force output in either wild-type or *mdx* muscle was not significantly affected by sildenafil treatment. Collectively, these findings suggest that sildenafil did not affect *mdx* diaphragm fatigue resistance.

### Sildenafil exhibits an anti-fibrotic activity in the *mdx* diaphragm

We investigated potential mechanisms for the sildenafil-mediated improvement in respiratory muscle strength and focused initially on fibrosis, which is thought to contribute to muscle weakness [6,7]. We examined two markers of fibrosis, collagen I and fibronectin, in dystrophin-deficient diaphragm (Figure 2A [6]). Immunohistochemical analysis revealed that collagen I and fibronectin are expressed at low levels around muscle fibres in normal diaphragm, but are found at much higher amounts in *mdx* muscle as expected (Figure 2A). Importantly, both collagen I and fibronectin were markedly decreased by sildenafil treatment (Figure 2A). To provide a quantitative measure of the anti-fibrotic activity of sildenafil, fibronectin levels in diaphragm muscles were measured by western immunoblotting (Figures 2B and 2C). Fibronectin protein expression was five-fold higher ( $p < 0.01$ ) in vehicle-treated *mdx* mice than in wild-type controls (Figures 2B and 2C). In agreement with immunohistochemical findings, an approximately 40% reduction ( $p < 0.05$ ) in fibronectin expression was observed in sildenafil-treated *mdx* diaphragms compared with *mdx* controls (Figures 2B and 2C). These data suggested an important role for sildenafil in slowing the development of fibrosis.

To further understand the anti-fibrotic properties of sildenafil, we investigated the impact of sildenafil on the expression of TNF $\alpha$  and TGF $\beta$ 1, known to promote fibrosis in *mdx* muscle [37]. TNF $\alpha$  transcript expression was three-fold higher in *mdx* diaphragms compared with controls. This increase is consistent with previous reports in DMD patients and *mdx* mice (Figure 3A [38–40]). Sildenafil-mediated PDE5 inhibition significantly ( $p < 0.05$ ) reduced *mdx* diaphragm TNF $\alpha$  expression to levels indistinguishable from wild-type controls (Figure 3A). These data suggest that reductions in TNF $\alpha$  could contribute to decreased fibrosis and increased diaphragm muscle strength.

The pro-fibrotic activity of TNF $\alpha$  in *mdx* mice may result from its ability to increase TGF $\beta$ 1 expression, since TNF $\alpha$  blockade can reduce TGF $\beta$ 1 and collagen I expression to wild-type

levels [41]. To investigate the possibility that TNF $\alpha$  normalization reduced TGF $\beta$ 1, thereby reducing fibrosis, we measured TGF $\beta$ 1 expression. As expected, TGF $\beta$ 1 expression was increased more than four-fold ( $p < 0.01$ ) in vehicle-treated *mdx* diaphragm compared with either treated or untreated wild-type controls (Figure 3B). But sildenafil did not impact TGF $\beta$ 1 expression in *mdx* diaphragms (Figure 3B). These data suggest that the regulation of TGF $\beta$ 1 transcript expression by TNF $\alpha$  in dystrophic muscle may not be as tightly coupled as previously thought. It should be noted that these data do not diminish the importance of TGF $\beta$ 1 in dystrophic muscle fibrosis or preclude an impact of sildenafil on TGF $\beta$ 1 signalling that may occur independently of TGF $\beta$ 1 transcript expression changes.

One additional line of evidence also supported the idea that sildenafil may work by opposing aberrant extracellular matrix (ECM) organization. Matrix metalloproteinase-13 (MMP-13) expression is positively regulated by TNF $\alpha$  and may play a role in fibrosis [42]. MMP-13 expression was more than 2.5-fold higher ( $p < 0.01$ ) in vehicle-treated *mdx* muscle than in wild-type controls (Figure 3C). As predicted, MMP-13 expression was also significantly decreased ( $p < 0.05$ ) by sildenafil in *mdx* diaphragms relative to controls (Figure 3C). Thus, normalization of TNF $\alpha$  could account for decreased MMP-13 expression. These data suggest that MMP-13 may contribute to aberrant ECM organization in *mdx* muscle and highlight a previously unappreciated link between NO–cGMP signalling and matrix metalloproteinase pathways. To the best of our knowledge, MMP-13 has not been previously implicated in dystrophic pathology. Together, these data strongly suggest that sildenafil can significantly reduce fibrotic deposition in dystrophic diaphragm and may do so, at least in part, by acting through TNF $\alpha$ - and MMP-13.

In addition to fibrosis, *mdx* diaphragm myofibres exhibit characteristically high levels of central nucleation that reflect substantial muscle breakdown and regeneration (Figures 4A and 4B) [29]. The fraction of muscle cells with centrally localized nuclei is a widely used measure of muscle degeneration and regeneration. About 60% ( $p < 0.01$ ) of *mdx* diaphragm muscle cells are centrally nucleated compared with ~4% in wild-type controls (Figures 4A and 4B). Central nucleation was unaffected by sildenafil treatment in both wild-type and *mdx* muscle (Figures 4A and 4B). Similarly, sildenafil also did not affect central nucleation frequency in *mdx* tibialis anterior hindlimb muscles (Supplementary Figures 2A and 2B). Muscle degeneration or damage can also lead to elevated serum creatine kinase (CK) activity or hyperCKaemia. In dystrophic muscle, sustained hyperCKaemia is a diagnostic biomarker and is also thought to represent ongoing muscle damage. As expected, circulating CK levels were significantly elevated in *mdx* mice compared with controls, but were unaffected by sildenafil-mediated PDE5 inhibition (Figure 5). These findings are consistent with previous reports that circulating CK activity in normal or *mdx* adult mice is unaffected by changes in nNOS signalling [12,21,23]. Thus, the strength-enhancing and anti-fibrotic benefits of sildenafil were independent of a change in the balance of degeneration to regeneration or serum CK activity.

### **Sildenafil reduces extracellular dye accumulation in *mdx* diaphragms**

Another key pathological characteristic of dystrophin-deficient muscle is its increased permeability to extracellular tracer dyes, such as Evans Blue dye (EBD). Increased dye



exclusion ability correlates well with reductions in fibrosis and improved muscle health [43,44]. Therefore, based on the attenuation of fibrosis, we hypothesized that sildenafil-treated *mdx* diaphragm muscles would also exhibit improved dye exclusion (Figure 6). Vehicle-treated wild-type diaphragm muscles were largely impermeable to EBD (Figure 6A). In contrast, untreated *mdx* diaphragms exhibited pronounced EBD accumulation (Figure 6A). Importantly, sildenafil significantly reduced *mdx* diaphragm permeability to EBD (Figure 6A). Quantification of EBD accumulation revealed a 40% reduction ( $p < 0.01$ ) in EBD uptake in *mdx* diaphragms compared with *mdx* controls (Figure 6B). These data suggest that sildenafil can also improve dystrophic muscle health by attenuating membrane permeability. The EBD exclusion assay results correlate well with decreased contractile dysfunction and fibrosis and indicate that sildenafil significantly improved both *mdx* diaphragm integrity and function.

## Discussion

Despite major advances in non-invasive ventilatory support, respiratory failure stemming from skeletal muscle weakness remains the leading cause of morbidity and mortality in DMD. To address this pathology, new, safe, efficacious, and cost-effective therapies are required. The major finding of the present study is that chronic sildenafil treatment significantly reduced diaphragm respiratory muscle weakness and fibrosis in the *mdx* mouse model of DMD. This study provides compelling new support for the therapeutic utility of targeting defective NO–cGMP signalling in dystrophin-deficient muscle with PDE5 inhibitors.

The first finding was the novel demonstration that chronic amplification of NO signalling by sildenafil enhanced *mdx* diaphragm strength by 15%. This increase appears modest only until it is compared with existing steroid therapy for DMD, which does not affect dystrophin-deficient diaphragm specific force and improves *mdx* hindlimb muscle strength by ~26% [31,32,35]. Furthermore, from a clinical point of view, if this sildenafil-mediated improvement in diaphragm strength were to translate from mouse to human, this would still constitute a significant advance in therapy and a very important addition to existing clinical treatment options for respiratory dysfunction, particularly for older DMD patients. Surprisingly, given that nNOS enzymes promote fatigue resistance, sildenafil did not impact *mdx* diaphragm muscle fatigue, suggesting that the cGMP pool regulated by PDE5 does not play a role in diaphragm fatigue.

These findings raise the question as to how sildenafil increases *mdx* diaphragm strength. Although the precise mechanisms remain to be elucidated, this study implicates several pathways that may act separately or in concert to improve *mdx* muscle strength. First, sildenafil may enhance strength by improving diaphragm tissue perfusion. Indeed, given the vasoregulatory role of nNOS $\mu$  and that sildenafil is a potent vasodilator, improved diaphragm tissue perfusion may contribute to increased strength by reducing ischaemic damage [8,17–19]. However, neither restored nNOS $\mu$  vasoregulatory activity nor acute sildenafil-mediated muscle perfusion increases *mdx* hindlimb skeletal muscle strength [20,23]. These studies suggest that sildenafil's vasodilatory activity has little or no effect on *mdx* diaphragm strength and certainly none on fatigue. However, other factors may be at

play here that influence sildenafil's impact including muscle-specific differences (Supplementary Figure 1A) as well as the duration of drug treatment. Thus, mechanisms other than vasodilation *per se* appear responsible for the impact of prolonged PDE5 inhibition on *mdx* diaphragm contractility.

One likely contributing mechanism to the sildenafil-mediated increase in *mdx* diaphragm strength is the substantial reduction of fibrosis. In DMD patients, fibrosis may cause skeletal muscle weakness including diaphragm dysfunction, which in turn decreases chest wall compliance and increases work required for breathing [7]. Left ventricle fibrosis impairs wall movement and promotes ventricular arrhythmias in DMD patients [2]. Thus, fibrosis is an important pathogenic feature in muscular dystrophy [37]. In *mdx* mice, extensive diaphragm fibrosis occurs after the onset of diaphragm weakness; therefore, fibrosis does not cause early diaphragm weakness in young (~6 weeks old) *mdx* mice [45]. However, with time, there is a progressive decline in diaphragm specific force that parallels the development of fibrosis, which is similar to findings in DMD [7,46]. Thus, fibrosis likely contributes to muscle weakness in older *mdx* mice. In this study, sildenafil treatment markedly reduced deposition of collagen I and fibronectin in the *mdx* diaphragm (Figure 2A). As expected, the attenuation of fibrosis was associated with enhanced diaphragm contractility in sildenafil-treated 17-week-old *mdx* mice. These data are consistent with the findings that tadalafil can qualitatively reduce diaphragm fibrosis and that NO can oppose cardiac fibrosis and dysfunction in *mdx* mice [19,22]. Taken together, this body of work provides compelling evidence that NO–cGMP pathways oppose fibrosis in dystrophin-deficient muscle. These data support the clinical relevance of fibrosis to dystrophic muscle dysfunction and the potential therapeutic utility of targeting fibrotic pathways with sildenafil.

What are the mechanisms by which sildenafil reduces diaphragm fibrosis? Since sildenafil (inhibits PDE5 and PDE1c) and tadalafil (inhibits PDE5 and PDE11) both decrease fibrosis, we conclude that PDE5 inhibition is responsible for attenuating *mdx* diaphragm fibrosis [19]. Furthermore, sildenafil normalized TNF $\alpha$  cytokine expression, suggesting a plausible downstream target of increased cGMP (Figure 3A). Excessive TNF $\alpha$  signalling causes inflammation, fibrosis, muscle catabolism, and vascular dysfunction, as well as skeletal (diaphragm) and cardiac muscle weakness [47–51]. TNF $\alpha$  is elevated in DMD patients and in *mdx* mice (increasing = 4 weeks of age) and may promote fibrosis and muscle weakness (Figure 3A [29,38–41]). Indeed, TNF $\alpha$  causes muscle necrosis, fibrosis, weakness, and respiratory dysfunction in adult *mdx* mice [40,52–54]. These studies provide compelling evidence that the sildenafil-mediated normalization of TNF $\alpha$  expression could lead to a reduction in *mdx* diaphragm fibrosis and contractile dysfunction. In summary, our current working model is that sildenafil-mediated TNF $\alpha$  normalization directly increases diaphragm strength in two ways: (1) by alleviating the force-depressing activity of TNF $\alpha$ , particularly in younger *mdx* mice; and (2) by indirectly enhancing diaphragm contractility in older *mdx* mice by inhibiting the pro-fibrotic activity of TNF $\alpha$ .

The anti-fibrotic action of sildenafil may also result from an impact on MMP-13 (Figure 3C). TNF $\alpha$  positively regulates the expression of MMP-13, a collagenase that regulates extracellular matrix (ECM) degradation and can promote fibrosis [42,55,56]. Importantly,



MMP-13 may have a role in skeletal muscle regeneration and repair [57]. MMP-13 levels were significantly elevated in the *mdx* diaphragm, consistent with the profibrotic extracellular environment (Figure 3C). Sildenafil also reduced MMP-13 transcript levels, which is consistent with TNF $\alpha$  as a positive regulator of MMP-13, although it is also possible that reductions in MMP-13 expression occur independently of TNF $\alpha$  (Figure 3C). Interestingly, MMP-13 is also a key activator of MMP-9, whose excessive activity can worsen *mdx* pathology [55,58]. So, decreasing MMP-13 may result in a beneficial reduction in MMP-9. Further studies are required to determine how changes in TNF $\alpha$  and MMP-13 message levels correlate with protein expression and activity. These data suggest that the anti-fibrotic impact of PDE5 inhibition in *mdx* diaphragm could result from the normalization of TNF $\alpha$ , which may in turn attenuate the expression of pathogenic MMPs including MMP-13 and possibly MMP-9, thereby promoting a more normal ECM.

Sildenafil-mediated reductions in fibrosis and weakness correlated well with decreased Evans Blue dye (EBD) accumulation in *mdx* diaphragms, consistent with improved muscle integrity (Figure 6). This is consistent with reduced EBD uptake in muscles of 4-week-old *mdx* mice treated with tadalafil *in utero* [19]. Sarcolemmal microtears are thought to be one mechanism by which EBD enters muscle cells; however, other mechanisms have been proposed [59]. Thus, the conventional interpretation for reduced EBD uptake is that sildenafil-treated *mdx* mice have less muscle damage or microtears. In this case, we would also expect a reduction in both hyperCKaemia and central nucleation; however, both of these pathological indices were unaffected by sildenafil. An absence of impact of sildenafil on central nucleation may reflect the timing of drug administration. Central nucleation reflects the balance of muscle degeneration to regeneration and increases rapidly during the first weeks of life in *mdx* muscle before plateauing. Administration of sildenafil to 3-week-old *mdx* mice simply may have been too late to impact the degree of central nucleation. Another possibility is that sildenafil may have simultaneously decreased degeneration (reflected in decreased diaphragm muscle fibrosis and increased muscle strength) and improved regeneration, leaving total levels of central nucleation apparently unchanged. Further studies are required to address these possibilities. These data suggest that muscle EBD accumulation (or influx) and creatine kinase efflux across the sarcolemma are distinct processes with unique sensitivities to NO-cGMP signalling. These data are consistent with recent reports of reductions in fibrosis and EBD accumulation that occurred independently of changes in hyperCKaemia in *mdx* mice [43,44]. Alternatively, persistent global hyperCKaemia may be explained by sildenafil improving *mdx* diaphragm integrity only, without affecting the integrity of other skeletal muscles. This possibility is consistent with the observation that sildenafil preferentially improves the function of respiratory, but not hindlimb, skeletal muscle. Collectively, these findings support a tight linkage between EBD exclusion and fibrosis in dystrophin-deficient muscle. Furthermore, mitigation of *mdx* dystrophic pathology resulting from either TNF $\alpha$  depletion or increased NO concentrations can also occur independently of changes in serum CK activity [21,23,60]. From a therapeutic perspective, reductions in global serum CK activity and central nucleation were clearly unnecessary for the sildenafil-mediated reduction in fibrosis, diaphragm muscle weakness, and cardiomyopathy [27]. In studies targeting defective NO signalling in

muscular dystrophy, caution must be exercised to prevent overreliance on central nucleation and hyperCKaemia as a measure of therapeutic impact.

In conclusion, we have demonstrated that chronic sildenafil treatment significantly reduces respiratory muscle weakness and fibrosis. These findings suggest a novel application of PDE5 inhibitors to the treatment of respiratory muscle dysfunction in DMD. Therapeutic approaches that address secondary pathology in DMD will ideally slow the progression of both respiratory dysfunction and cardiomyopathy. Such approaches should also be safe, cost-effective, useful in combination with existing corticosteroid treatments, and easily implementable. These therapies can potentially buy time and improve quality of life until more comprehensive treatments directed at the primary gene defect become available. We previously demonstrated that sildenafil reduces cardiomyopathy in *mdx* mice and thus appears to meet the requirements of a therapeutic agent targeting secondary pathology. Therefore, sildenafil shows promise as an adjunct therapeutic for dystrophic disease. Importantly, these findings may be broadly applicable to other neuromuscular diseases that lack normal NO signalling pathway function [20].

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Dr Kimberley Craven for critical editing of the manuscript. This research was supported by NIH grants NS33145 (SCF), NS59514 (SCF and JAB), and AR056221 (SCF and JAB), and by a Muscular Dystrophy Association Development Grant (JMP), a Parent Project Muscular Dystrophy Investigator Award (SCF), the Weisman Fellowship from Parent Project Muscular Dystrophy (NPW), and Charlie's Fund (SCF and JAB).


## References

- Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 1987; 51:919–928. [PubMed: 3319190]
- Finsterer J, Stöllberger C. The heart in human dystrophinopathies. *Cardiology*. 2003; 99:1–19. [PubMed: 12589117]
- Chen YW, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGF $\beta$  in Duchenne muscular dystrophy. *Neurology*. 2005; 65:826–834. [PubMed: 16093456]
- Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. *Curr Opin Rheumatol*. 2005; 17:707–713. [PubMed: 16224247]
- Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. *J Clin Invest*. 1995; 96:1137–1144. [PubMed: 7635950]
- Hantai D, Labat-Robert J, Grimaud JA, et al. Fibronectin, laminin, type I, III and IV collagens in Duchenne's muscular dystrophy, congenital muscular dystrophies and congenital myopathies: an immunocytochemical study. *Connect Tissue Res*. 1985; 13:273–281. [PubMed: 3161692]
- Desguerre I, Mayer M, Leturcq F, et al. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. *Neuropathol Exp Neurol*. 2009; 68:762–773.
- Thomas GD, Sander M, Lau KS, et al. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. *Proc Natl Acad Sci U S A*. 1998; 95:15090–15095. [PubMed: 9844020]

9. Thomas GD, Shaul PW, Yuhanna IS, et al. Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. *Circ Res.* 2003; 92:554–560. [PubMed: 12600881]
10. Suzuki N, Motohashi N, Uezumi A, et al. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. *J Clin Invest.* 2007; 117:2468–2476. [PubMed: 17786240]
11. Percival JM, Anderson KN, Gregorevic P, et al. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. *PLoS One.* 2008; 3:e3387. [PubMed: 18852886]
12. Percival JM, Anderson KN, Huang P, et al. Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle. *J Clin Invest.* 2010; 120:816–826. [PubMed: 20124730]
13. Percival JM, Adamo CM, Beavo JA, et al. Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the *mdx* mouse model of Duchenne muscular dystrophy. *Handb Exp Pharmacol.* 2011; 204:323–344. [PubMed: 21695647]
14. Percival JM. nNOS regulation of skeletal muscle fatigue and exercise performance. *Biophys Rev.* 2011; 3:209–217.
15. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell.* 1995; 82:743–752. [PubMed: 7545544]
16. Chang WJ, Iannaccone ST, Lau KS, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. *Proc Natl Acad Sci U S A.* 1996; 93:9142–9147. [PubMed: 8799168]
17. Ito K, Kimura S, Ozasa S, et al. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in *mdx* mice. *Hum Mol Genet.* 2006; 15:2266–2275. [PubMed: 16777842]
18. Sato K, Yokota T, Ichioka S, et al. Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. *Acta Myol.* 2008; 27:30–36. [PubMed: 19108575]
19. Asai A, Sahani N, Kaneki M, et al. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. *PLoS One.* 2007; 2:e806. [PubMed: 17726536]
20. Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. *Nature.* 2008; 456:511–515. [PubMed: 18953332]
21. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in *mdx* mice. *J Cell Biol.* 2001; 155:123–131. [PubMed: 11581289]
22. Wehling-Henricks M, Jordan MC, Roos KP, et al. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. *Hum Mol Genet.* 2005; 14:1921–1933. [PubMed: 15917272]
23. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. *J Clin Invest.* 2009; 119:624–635. [PubMed: 19229108]
24. Cvelich RG, Roberts SC, Brown JN. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. *Ann Pharmacother.* 2011; 45:1551–1558. [PubMed: 22116990]
25. Hofmann F, Feil R, Kleppisch T, et al. Function of cGMP-dependent protein kinases as revealed by gene deletion. *Physiol Rev.* 2006; 86:1–23. [PubMed: 16371594]
26. Craven KB, Zagotta WN. CNG and HCN channels: two peas, one pod. *Annu Rev Physiol.* 2006; 68:375–401. [PubMed: 16460277]
27. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the *mdx* mouse model of Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A.* 2010; 107:19079–19083. [PubMed: 20956307]
28. Khairallah M, Khairallah RJ, Young ME, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. *Proc Natl Acad Sci U S A.* 2008; 105:7028–7033. [PubMed: 18474859]

29. Stedman HH, Sweeney HL, Shrager JB, et al. The *mdx* mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. *Nature*. 1991; 352:536–539. [PubMed: 1865908]
30. Gregorevic P, Plant DR, Leeding KS, et al. Improved contractile function of the *mdx* dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. *Am J Pathol*. 2002; 161:2263–2272. [PubMed: 12466140]
31. Yang L, Luo J, Petrof BJ. Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (*mdx*) mouse diaphragm. *Muscle Nerve*. 1998; 21:394–397. [PubMed: 9486869]
32. Hinkle RT, Lefever FR, Dolan ET, et al. Corticotrophin releasing factor 2 receptor agonist treatment significantly slows disease progression in *mdx* mice. *BMC Med*. 2007; 5:18. [PubMed: 17626629]
33. Dellorusso C, Crawford RW, Chamberlain JS, et al. Tibialis anterior muscles in *mdx* mice are highly susceptible to contraction-induced injury. *J Muscle Res Cell Motil*. 2001; 22:467–475. [PubMed: 11964072]
34. Lynch GS, Hinkle RT, Faulkner JA. Power output of fast and slow skeletal muscles of *mdx* (dystrophic) and control mice after clenbuterol treatment. *Exp Physiol*. 2000; 85:295–299. [PubMed: 10825417]
35. Baltgalvis KA, Call JA, Nikas JB, et al. Effects of prednisolone on skeletal muscle contractility in *mdx* mice. *Muscle Nerve*. 2009; 40:443–454. [PubMed: 19618428]
36. Wehling-Henricks M, Oltmann M, Rinaldi C, et al. Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. *Hum Mol Genet*. 2009; 18:3439–3451. [PubMed: 19542095]
37. Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. *J Neuropathol Exp Neurol*. 2010; 69:771–776. [PubMed: 20613637]
38. Porreca E, Guglielmi MD, Uncini A, et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. *Thromb Haemost*. 1999; 81:543–546. [PubMed: 10235436]
39. Saito K, Kobayashi D, Komatsu M, et al. A sensitive assay of tumor necrosis factor alpha in sera from Duchenne muscular dystrophy patients. *Clin Chem*. 2000; 46:1703–1704. [PubMed: 11017956]
40. Huang P, Zhao XS, Fields M, et al. Imatinib attenuates skeletal muscle dystrophy in *mdx* mice. *FASEB J*. 2009; 23:2539–2548. [PubMed: 19289603]
41. Gosselin LE, Martinez DA. Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. *Muscle Nerve*. 2004; 30:244–246. [PubMed: 15266643]
42. Borden P, Solymer D, Sucharczuk A, et al. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. *J Biol Chem*. 1996; 271:23577–23581. [PubMed: 8798568]
43. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. *Nature Med*. 2007; 13:204–210. [PubMed: 17237794]
44. Heydemann A, Ceco E, Lim JE, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. *J Clin Invest*. 2009; 119:3703–3712. [PubMed: 19884661]
45. Coirault C, Pignol B, Cooper RN, et al. Severe muscle dysfunction precedes collagen tissue proliferation in *mdx* mouse diaphragm. *J Appl Physiol*. 2003; 94:1744–1750. [PubMed: 12679345]
46. Faulkner JA, Ng R, Davis CS, et al. Diaphragm muscle strip preparation for evaluation of gene therapies in *mdx* mice. *Clin Exp Pharmacol Physiol*. 2008; 35:725–729. [PubMed: 18215182]
47. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. *Annu Rev Cell Biol*. 1993; 9:317–343. [PubMed: 8280464]
48. Walley KR, Hebert PC, Wakai Y, et al. Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. *J Appl Physiol*. 1994; 76:1060–1067. [PubMed: 8005845]
49. Wilcox PG, Wakai Y, Walley KR, et al. Tumor necrosis factor alpha decreases *in vivo* diaphragm contractility in dogs. *Am J Respir Crit Care Med*. 1994; 150:1368–1373. [PubMed: 7952566]


50. Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor- $\alpha$  causes oxidative stress and contractile dysfunction in mouse diaphragm. *Circulation*. 2000; 102:1690–1696. [PubMed: 11015349]
51. Hardin BJ, Campbell KS, Smith JD, et al. TNF- $\alpha$  acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. *J Appl Physiol*. 2008; 104:694–699. [PubMed: 18187611]
52. Gosselin LE, Barkley JE, Spencer MJ, et al. Ventilatory dysfunction in *mdx* mice: impact of tumor necrosis factor- $\alpha$  deletion. *Muscle Nerve*. 2003; 28:336–343. [PubMed: 12929194]
53. Grounds MD, Torrisi J. Anti-TNF $\alpha$  (Remicade) therapy protects dystrophic skeletal muscle from necrosis. *FASEB J*. 2004; 18:676–682. [PubMed: 15054089]
54. Piers AT, Lavin T, Radley-Crabb HG, et al. Blockade of TNF *in vivo* using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic *mdx* and normal mice. *Neuromuscul Disord*. 2011; 21:132–141. [PubMed: 21055937]
55. Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human matrix metalloproteinase-13. *Crit Rev Biochem Mol Biol*. 2002; 37:149–166. [PubMed: 12139441]
56. Uchinami H, Seki E, Brenner DA, et al. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. *Hepatology*. 2006; 44:420–429. [PubMed: 16871591]
57. Wu N, Jansen ED, Davidson JM. Comparison of mouse matrix metalloproteinase 13 expression in free-electron laser and scalpel incisions during wound healing. *J Invest Dermatol*. 2003; 121:926–932. [PubMed: 14632214]
58. Li H, Mittal A, Makonchuk DY, et al. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. *Hum Mol Genet*. 2009; 18:2584–2598. [PubMed: 19401296]
59. Allen DG, Whitehead NP. Duchenne muscular dystrophy—what causes the increased membrane permeability in skeletal muscle? *Int J Biochem Cell Biol*. 2011; 43:290–294. [PubMed: 21084059]
60. Spencer MJ, Marino MW, Winckler WM. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. *Neuromuscul Disord*. 2000; 10:612–619. [PubMed: 11053690]




**Figure 1.** Sildenafil increases *mdx* diaphragm muscle specific force output. (A) Maximal specific force output of wild-type and *mdx* diaphragm strips treated with vehicle or sildenafil. Treated *mdx* mice were significantly stronger than untreated *mdx* controls. (B) Representative traces of fatigue resistance profiles of wild-type and *mdx* diaphragms treated with vehicle or sildenafil. *Mdx* muscles exhibited significant muscle fatigue compared with wild-type controls, with force deficits during repetitive stimulation and recovery phases (marked post-exercise weakness). Sildenafil treatment did not impact the fatigue resistance of wild-type or *mdx* diaphragm muscle.  $p < 0.05$  refers to the difference in force output of untreated wild-type and untreated *mdx* diaphragms during repetitive stimulation.  $p < 0.0001$  refers to the difference in force output of untreated wild-type and untreated *mdx* diaphragms during the recovery phase. (C) Mean final force output at the end of the repetitive stimulation phase in wild-type and *mdx* diaphragm strips treated with vehicle or sildenafil of a fatigue protocol. *Mdx* muscles show a significant force deficit at the end of repetitive stimulation compared with wild-type. Sildenafil has no impact on the final force output in




wild-type or *mdx* diaphragms. Wild-type untreated and sildenafil-treated:  $n = 5$  each. *mdx* untreated and sildenafil-treated:  $n = 5$  and 9, respectively.



**Figure 2.** Sildenafil reduces endomysial fibrosis in the *mdx* diaphragm. (A) Representative diaphragm sections stained with collagen I (top row) and fibronectin (bottom row) antibodies. Both collagen I and fibronectin are markers of fibrosis in dystrophin-deficient skeletal muscle. Sildenafil reduced both collagen I and fibronectin deposition around *mdx* diaphragm muscle fibres. (B) Representative western blot of global fibronectin protein expression in vehicle and sildenafil-treated *mdx* diaphragms. *Mdx* diaphragms exhibit high levels of fibronectin that are significantly decreased by sildenafil treatment. (C) Western blot quantitation of fibronectin protein levels. Sildenafil significantly reduced fibronectin expression in the *mdx* diaphragm. Scale bars in A: 100  $\mu$ m (top row) and 50  $\mu$ m (bottom row). Wild-type ( $n = 5$ ); vehicle and sildenafil-treated *mdx* mice ( $n = 4$  each).


**Figure 3.**

Chronic sildenafil treatment normalizes TNF $\alpha$  and decreases MMP-13 expression, but does not impact TGF $\beta$ 1 in *mdx* diaphragms. The impact of sildenafil on regulators of inflammation (TNF $\alpha$ ) and fibrosis (TNF $\alpha$ , MMP-13, TGF $\beta$ 1) was evaluated at the transcript level by quantitative PCR. (A) TNF $\alpha$  expression was elevated 3.2-fold in *mdx* diaphragm tissue, but normalized to wild-type levels by sildenafil treatment. (B) Profibrotic TGF $\beta$ 1 transcript expression was substantially elevated in *mdx* diaphragms 5.8-fold, but unaffected by sildenafil treatment. (C) MMP-13 expression was increased 2.7-fold in *mdx* diaphragm and was also significantly reduced by sildenafil. Wild-type vehicle- ( $n = 5$ ), wild-type sildenafil- ( $n = 3$ ), *mdx* vehicle- ( $n = 6$ ), and sildenafil-treated *mdx* mice ( $n = 9$ ).




**Figure 4.**

Chronic sildenafil treatment did not impact central nucleation in the *mdx* diaphragm. (A) Representative images of haematoxylin and eosin-stained diaphragm muscle sections from vehicle- and sildenafil-treated wild-type (top row) and *mdx* (bottom row) mice. *Mdx* diaphragms revealed no overt differences in inflammatory cell infiltration or muscle necrosis. (B) Quantitation of the fraction of muscle fibres with centrally localized nuclei or degeneration/regeneration index. The fraction of centrally nucleated muscle cells was over 60% in *mdx* diaphragms compared with wild-type controls. Sildenafil treatment did not impact the degeneration/regeneration index. Scale bar = 100  $\mu$ m.  $n = 4$  for each group, with all four diaphragms from each group haematoxylin and eosin-stained and analysed for central nucleation.



**Figure 5.**

Global serum creatine kinase activity is unaffected by sildenafil treatment. Elevated serum CK (hyperCKaemia) is typically used as a marker of muscle damage. Both vehicle- and sildenafil-treated wild-type animals show characteristically low CK activity. *mdx* mice exhibited characteristic hyperCKaemia, marked by high levels of serum activity that were unaffected by sildenafil treatment.  $n = 3$  and  $4$  for vehicle- and sildenafil-treated wild-type mice, respectively.  $n = 4$  and  $5$  for vehicle- and sildenafil-treated *mdx* mice, respectively.



**Figure 6.** Sildenafil reduces sarcolemmal and vascular permeability of *mdx* diaphragm muscle tissue. (A) Whole mounts of diaphragm respiratory muscles showing extensive accumulation of Evans Blue dye (EBD) in *mdx* diaphragms which was reduced by sildenafil treatment. (B) Quantification of EBD uptake. Sildenafil significantly reduces EBD uptake by the *mdx* diaphragm. EBD uptake studies were performed in four mice for each group and representative images are shown.